Ramipril Capsule
Product Images NDC 51655-975

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-975-52 (51655 975 52 Rev A 02 23)

This is a description of Ramipril, a medication presented in the form of capsules. Each capsule contains 2.5mg of Ramipril. It's recommended to keep the medication in its original container and in a controlled temperature environment not exceeding 25°C. The medication should be stored out of the reach of children. The description includes the NDC number, LCN, and other relevant details of the product. This medication is available only with a doctor's prescription.*

FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

This appears to be a graph or chart of some sort displaying the proportion of patients on Ramipril over a certain period of time. The values range from 0.0 to 0.2 and there is a noticeable drop at the end with a p-value of 0.0001. The X-axis appears to measure the days of follow-up, ranging from 500 to 1500. However, without any additional context, it is difficult to determine the precise meaning or purpose of this graph.*

FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

This appears to be a table containing information related to a medical study. It references cardiovascular disease, diabetes, age, sex, hypertension, coronary artery disease, prior myocardial infraction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The table includes a number of patients and an incidence of a composite outcome in the placebo group, as well as the relative risk in the Ramipril group with a confidence interval. Without additional context, it is difficult to provide further details on the study or its findings.*

FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.